Therapeutics News and Research

RSS

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

26 Aug 2015

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.

26 Aug 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

Chrono obtains second Fast Track SBIR grant award from NCI to support development of smoking cessation therapy

Chrono Therapeutics, a pioneer in digital drug therapy, today announced it has received a second Phase 1 and Phase 2 Fast Track Small Business Innovation Research (SBIR) grant award from the National Cancer Institute.

26 Aug 2015

Better drug design may soon be aided by Scripps scientists’ discoveries

For the first time, they have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output. These new findings could aid future drug design by giving scientists an edge in fine tuning the signal between these partnered proteins—and the drug’s course of action.

25 Aug 2015

New TSRI study may have important implications for better drug design

Scientists from The Scripps Research Institute Florida campus have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output. These new findings could aid future drug design by giving scientists an edge in fine tuning the signal between these partnered proteins—and the drug's course of action.

25 Aug 2015

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer.

25 Aug 2015

Study shows beta blockers may benefit women with ovarian cancer

A new analysis of patient records indicates that certain drugs taken to improve heart health may also have anti-cancer properties.

25 Aug 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015.

25 Aug 2015

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares.

24 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030.

23 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

Researchers establish structure of important tumor-suppressing protein

An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN. Their findings provide new insights into how the protein regulates cell growth and how mutations in the gene that encodes the protein can lead to cancer.

21 Aug 2015

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus Biotherapeutics today announced that they have entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are an important class of proteins that play a key role in the innate immune system.

20 Aug 2015

60P to commence Phase II clinical trial among dengue fever patients

60 Degrees Pharmaceuticals, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients.

20 Aug 2015

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.

20 Aug 2015

Therapeutics News and Research

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Chrono obtains second Fast Track SBIR grant award from NCI to support development of smoking cessation therapy

Better drug design may soon be aided by Scripps scientists’ discoveries

New TSRI study may have important implications for better drug design

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Study shows beta blockers may benefit women with ovarian cancer

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

Researchers establish structure of important tumor-suppressing protein

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

60P to commence Phase II clinical trial among dengue fever patients

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

Advancing therapeutic biopolymer development eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News